Ravi Maharjan , Shavron Hada , I. Jeong Shin , Ki Hyun Kim , Nam Ah Kim , Seong Hoon Jeong
{"title":"抗菌防腐剂对单克隆抗体曲妥珠单抗蛋白折叠稳定性和亚可见颗粒形成的影响。","authors":"Ravi Maharjan , Shavron Hada , I. Jeong Shin , Ki Hyun Kim , Nam Ah Kim , Seong Hoon Jeong","doi":"10.1016/j.ejpb.2025.114835","DOIUrl":null,"url":null,"abstract":"<div><div>To prevent microbial contamination, antimicrobial preservatives need to be added in multi-dose biopharmaceuticals; however, it often introduces risks to protein stability, potentially compromising therapeutic efficacy. In this study, we investigated the effects of different preservatives (benzyl alcohol, m-cresol, phenoxyethanol, and benzalkonium chloride) on the biophysical stability of trastuzumab, a monoclonal antibody widely used for treatment of HER2 receptor-positive cancers. Among the preservatives tested, benzyl alcohol (1.0 % v/v) and m-cresol (0.3 % w/v) significantly reduced the monomeric content after 5 days of end-over-end agitation stress. Benzyl alcohol was associated with a surge in nano- to micro-sized particles (21-fold increase) and decreased thermal stability (Δ<em>T<sub>m</sub></em>: −5.39 °C). m-Cresol uniquely triggered visible particle formation (>100 µm) within 72 h, raising concerns for injectable biologics. Benzalkonium chloride (0.01 %–0.04 % w/v) exhibited inconsistent concentration-dependent behavior, initially showing increase in subvisible aggregates before stabilizing through micelle formation at higher concentrations, albeit with irreversible secondary structural shifts toward β-sheet motifs. Conversely, phenoxyethanol (0.5 % v/v) exhibited higher compatibility, preserved the monomeric content, and suppressed particle generation to baseline levels. These findings underscore the necessity of preservative-specific compatibility assessments in formulation design for therapeutic biologics, positioning phenoxyethanol as a promising candidate for trastuzumab preservation owing to the balance between its antimicrobial efficacy and minimal destabilization.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"215 ","pages":"Article 114835"},"PeriodicalIF":4.3000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of antimicrobial preservatives on protein folding stability and subvisible particle formation in monoclonal antibody trastuzumab\",\"authors\":\"Ravi Maharjan , Shavron Hada , I. Jeong Shin , Ki Hyun Kim , Nam Ah Kim , Seong Hoon Jeong\",\"doi\":\"10.1016/j.ejpb.2025.114835\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>To prevent microbial contamination, antimicrobial preservatives need to be added in multi-dose biopharmaceuticals; however, it often introduces risks to protein stability, potentially compromising therapeutic efficacy. In this study, we investigated the effects of different preservatives (benzyl alcohol, m-cresol, phenoxyethanol, and benzalkonium chloride) on the biophysical stability of trastuzumab, a monoclonal antibody widely used for treatment of HER2 receptor-positive cancers. Among the preservatives tested, benzyl alcohol (1.0 % v/v) and m-cresol (0.3 % w/v) significantly reduced the monomeric content after 5 days of end-over-end agitation stress. Benzyl alcohol was associated with a surge in nano- to micro-sized particles (21-fold increase) and decreased thermal stability (Δ<em>T<sub>m</sub></em>: −5.39 °C). m-Cresol uniquely triggered visible particle formation (>100 µm) within 72 h, raising concerns for injectable biologics. Benzalkonium chloride (0.01 %–0.04 % w/v) exhibited inconsistent concentration-dependent behavior, initially showing increase in subvisible aggregates before stabilizing through micelle formation at higher concentrations, albeit with irreversible secondary structural shifts toward β-sheet motifs. Conversely, phenoxyethanol (0.5 % v/v) exhibited higher compatibility, preserved the monomeric content, and suppressed particle generation to baseline levels. These findings underscore the necessity of preservative-specific compatibility assessments in formulation design for therapeutic biologics, positioning phenoxyethanol as a promising candidate for trastuzumab preservation owing to the balance between its antimicrobial efficacy and minimal destabilization.</div></div>\",\"PeriodicalId\":12024,\"journal\":{\"name\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"volume\":\"215 \",\"pages\":\"Article 114835\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0939641125002127\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125002127","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Effects of antimicrobial preservatives on protein folding stability and subvisible particle formation in monoclonal antibody trastuzumab
To prevent microbial contamination, antimicrobial preservatives need to be added in multi-dose biopharmaceuticals; however, it often introduces risks to protein stability, potentially compromising therapeutic efficacy. In this study, we investigated the effects of different preservatives (benzyl alcohol, m-cresol, phenoxyethanol, and benzalkonium chloride) on the biophysical stability of trastuzumab, a monoclonal antibody widely used for treatment of HER2 receptor-positive cancers. Among the preservatives tested, benzyl alcohol (1.0 % v/v) and m-cresol (0.3 % w/v) significantly reduced the monomeric content after 5 days of end-over-end agitation stress. Benzyl alcohol was associated with a surge in nano- to micro-sized particles (21-fold increase) and decreased thermal stability (ΔTm: −5.39 °C). m-Cresol uniquely triggered visible particle formation (>100 µm) within 72 h, raising concerns for injectable biologics. Benzalkonium chloride (0.01 %–0.04 % w/v) exhibited inconsistent concentration-dependent behavior, initially showing increase in subvisible aggregates before stabilizing through micelle formation at higher concentrations, albeit with irreversible secondary structural shifts toward β-sheet motifs. Conversely, phenoxyethanol (0.5 % v/v) exhibited higher compatibility, preserved the monomeric content, and suppressed particle generation to baseline levels. These findings underscore the necessity of preservative-specific compatibility assessments in formulation design for therapeutic biologics, positioning phenoxyethanol as a promising candidate for trastuzumab preservation owing to the balance between its antimicrobial efficacy and minimal destabilization.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.